semaglutide vs tirzepatide efficacy weight loss oral cardiovascular outcomes soul trial results 2024 2025 Trial Scorecard: SOUL Cardiovascular Outcomes Associated with Semaglutide

Carmot Therapeutics is now expanding the trials to include overweight and obese patients with type 2 diabetes, to assess further CT-868s impact on glycemic control, weight loss, and tolerability

Tirzepatide injections represent a dual-action GLP-1 and GIP receptor agonist that users typically administer once weekly into subcutaneous tissue

GLP-1 agonists have mixed cardiovascular effects

Tirzepatide is FDAapproved for specific indications, including type 2 diabetes and, at certain doses and brand names, chronic weight management in adults with defined BMI criteria plus at least one weight-related condition, when combined with lifestyle change